Targeting NAMPT‐OPA1 for treatment of senile osteoporosis
Aging Cell · 2025-03 · 24 (3)
DOI: 10.1111/acel.14400 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Cell, online erschienen am 14.11.2024. Verfasst von Chao-Wen Bai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Nicotinamide Phosphoribosyltransferase, Osteoporosis, Cytokines, GTP Phosphohydrolases. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China National Nuclear Corporation Young talent project, Scientific research project of Jiangsu Provincial Health Commission.
Abstract (Originalsprache)
Senescence of bone marrow mesenchymal stem cells (BMSCs) impairs their stemness and osteogenic differentiation, which is the principal cause of senile osteoporosis (SOP). Imbalances in nicotinamide phosphoribosyltransferase (NAMPT) homeostasis have been linked to aging and various diseases. Herein, reduction of NAMPT and impaired osteogenesis were observed in BMSCs from aged human and mouse. Knockdown of Nampt in BMSCs promotes lipogenic differentiation and increases age‐related bone loss. Overexpression of Nampt ameliorates the senescence‐associated (SA) phenotypes in BMSCs derived from aged mice, as well as promoting osteogenic potential. Mechanistically, NAMPT inhibits BMSCs senescence by facilitating OPA1 expression, which is essential for mitochondrial dynamics. The defect of NAMPT reduced mitochondrial membrane potential, interfered with mitochondrial fusion,and increased SA protein and phenotypes. More importantly, we have confirmed that P7C3, the NAMPT activator, is a novel strategy for reducing SOP bone loss. P7C3 treatment significantly prevents BMSCs senescence by improving mitochondrial function through the NAMPT‐OPA1 signaling axis. Taken together, these results reveal that NAMPT is a regulator of BMSCs senescence and osteogenic differentiation. P7C3 is a novel molecule drug to prevent the pathological progression of SOP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
- Institution of Neuroscience, Soochow University, Suzhou, Jiangsu, China.
- Suzhou Medical College, Soochow University, Suzhou, Jiangsu, China.
ORCID-Profile: Hua-Jian Shan
Förderung
- National Natural Science Foundation of China
- China National Nuclear Corporation Young talent project
- Scientific research project of Jiangsu Provincial Health Commission
- Jiangsu Provincial Medical Key Discipline (Laboratory) Cultivation Unit
- Social Development Key Programs of Jiangsu Province-Advanced Clinical Technology
- Natural Science Foundation of Jiangsu Province
- Youth Excellence Talent Program of the Second Affiliated Hospital of Soochow University
- Gusu health talent plan-special talents C
Zitieren
APA
Bai, C. W., Tian, B., Zhang, M. C., Qin, Q., Shi, X., Yang, X., Gao, X., Zhou, X. Z., Shan, H. J., & Bai, J. Y. (2025). Targeting NAMPT‐OPA1 for treatment of senile osteoporosis. Aging Cell, 24(3). https://doi.org/10.1111/acel.14400
Vancouver
Bai CW, Tian B, Zhang MC, Qin Q, Shi X, Yang X, et al. Targeting NAMPT‐OPA1 for treatment of senile osteoporosis. Aging Cell. 2025;24(3). doi:10.1111/acel.14400
BibTeX
@article{Bai2025,
author = {Bai, Chao-Wen and Tian, Bo and Zhang, Ming-Chao and Qin, Qin and Shi, Xin and Yang, Xi and Gao, Xiang and Zhou, Xiao-Zhong and Shan, Hua-Jian and Bai, Jin-Yu},
title = {Targeting NAMPT‐OPA1 for treatment of senile osteoporosis},
journal = {Aging Cell},
year = {2025},
volume = {24},
number = {3},
doi = {10.1111/acel.14400}
}
EUVIMED